Clinical trials
Respiratory Infection Virus clinical trials
Below are recruiting respiratory infection virus clinical trials, each written for real people, not researchers. We’re tracking 76 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06775405RecruitingPhase 3
Testing a new RSV treatment for hospitalized babies
This study tests a medicine called AK0529 for babies and toddlers hospitalized with RSV. It aims to see if the drug helps them recover faster and is safe for this age group.
BeijingAges 1 month–2 years - NCT07272434RecruitingPhase 3
RSV vaccine trial for adults 60 and older
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
Guangzhou, GuangdongAges 60 years+ - NCT07482657RecruitingPhase 2
Zelicapavir for RSV in infants and toddlers
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
BangkokAges 4 weeks–3 years - NCT05026749RecruitingPhase 3
Azithromycin for severe RSV breathing failure in young children
This trial tests whether azithromycin (an antibiotic) can improve outcomes for babies and young children in the ICU who have RSV causing serious breathing problems. It mainly looks at children who start strong breathing support soon after RSV symptoms begin.
Birmingham, AlabamaAges 3 days–2 years - NCT05045612RecruitingPhase 4
Antibiotics for certain viral lung infections in hospitalized adults
This trial studies whether giving antibiotics affects recovery in adults hospitalized with moderately severe infections caused by specific viruses (influenza, parainfluenza, RSV, or hMPV). It may help show when antibiotics are helpful or unnecessary for viral airway illness.
BergenAges 18 years+ - NCT06197152Recruiting
RSV severity markers in hospitalized adults
This study looks for markers in the blood that can tell how serious an RSV infection might become. If you are hospitalized with RSV and have breathing symptoms, this trial will follow your recovery and test for clues about your illness.
CréteilAges 18 years+ - NCT06643039Recruiting
Study on hospital-acquired respiratory virus infections
This trial looks at respiratory viruses caught in the hospital. If you are an adult patient or healthcare worker with flu-like symptoms that started while in the hospital, you may help researchers learn more about these infections.
BordeauxAges 18 years+ - NCT06684379RecruitingPhase 1/Phase 2
Two Doses of PRS CK STORM for Severe Viral Pneumonia
This study tests a new drug called PRS CK STORM to see if it can safely calm the body's overactive immune response (cytokine storm) in people with severe pneumonia from COVID-19, flu, or RSV who need oxygen. It aims to reduce inflammation and improve recovery.
Alcalá de Henares, MadridAges 18 years+ - NCT06735612Recruiting
RSV and COPD Flare-Ups Study
This study looks at whether RSV (a common respiratory virus) is linked to COPD flare-ups that need urgent care. By testing patients during a flare-up, researchers hope to understand how RSV affects COPD and find better ways to manage it.
BarcelonaAges 50 years+ - NCT06736288RecruitingPhase 4
Buccalin® tablets to prevent repeat lung infections
This trial tests whether Buccalin® tablets can help adults who get frequent lower respiratory infections (like bronchitis or COPD flare-ups). It's a phase 4 study collecting more data on safety and how well the medicine works to prevent these infections from coming back.
AlessandriaAges 18–99 - NCT06998251Recruiting
Immune response to strep pneumonia in older adults
This study looks at how the immune system in the nose and throat reacts to Streptococcus pneumoniae bacteria and viruses in adults aged 60-85. It may help researchers find better ways to prevent or treat pneumonia.
GenevaAges 60–85 - NCT07147517Recruiting
Tracking respiratory viruses in your community and home
This study tracks how respiratory viruses spread in the community and within households. It involves testing and collecting samples from people who are sick or healthy, to help better understand and prevent outbreaks.
La Jolla, CaliforniaAges Any age - NCT07229677Recruiting
Arbovirus and emerging virus infections study in Fiji
This study is looking at how viruses like those spread by mosquitoes (arboviruses) affect people in Fiji. If you join, researchers will track your health over time to find better ways to prevent and treat these infections.
Suva, CentralAges 6 years+ - NCT07239583Recruiting
RSV infection and health impact in older adults in Vietnam
This study looks at how common RSV (a virus that can cause serious breathing problems) is in older adults who are hospitalized with respiratory symptoms or worsening heart/lung conditions. By joining, you help researchers understand the virus and improve care for people your age.
Ho Chi Minh City, Southern VietnamAges 60 years+ - NCT06363370RecruitingPhase 3
Interferon inhalation for RSV in children under 2
This trial tests if an inhaled interferon solution can help children under 2 years old with a moderate to severe RSV lung infection. It aims to reduce symptoms like cough and trouble breathing.
Beijing, Beijing MunicipalityAges 2 months–2 years - NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75 - NCT05661032Recruiting
Testing new ways to identify respiratory viruses
This study tests “new technologies” to identify what virus is causing a respiratory illness, using samples taken from inside your nose. It may help doctors get faster, more accurate answers about the cause of your symptoms.
Portsmouth, HampshireAges Any age - NCT07582796RecruitingPhase 1/Phase 2
RSV Vaccine Study for Adults in China
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
Zigong, SichuanAges 18 years+ - NCT07633288RecruitingPhase 2
AP1189 Safety and Efficacy for Severe Respiratory Viral Infection
This trial tests whether an experimental drug called AP1189, added to standard hospital care, can help people hospitalized with severe breathing problems from viruses like COVID-19, flu, or RSV. The goal is to see if it reduces the need for mechanical ventilation or other life support.
Mostar, Herzegovina-Neretva CantonAges 18 years+ - NCT07658534RecruitingPhase 2/Phase 3
Ziresovir for high-risk adults with RSV
This trial tests an antiviral drug called Ziresovir in adults with RSV who have health conditions that make them high-risk, such as lung disease, heart disease, or a weakened immune system. It aims to see if the drug can reduce symptoms like coughing and shortness of breath.
Beijing, Beijing MunicipalityAges 18–85 - NCT07215871Enrolling by invitationPhase 1
Second H10N7 flu challenge for prior participants
This study tests whether people who have already been exposed to a lab-made H10N7 flu virus can be safely exposed again. It checks how their immune system responds and how long they shed the virus, in a controlled, isolated setting.
Bethesda, MarylandAges 18–55 - NCT06401720Enrolling by invitation
Flu immune response study by age
This study looks at how the immune system reacts to the flu in people of different ages. If you have flu symptoms and don't have cancer or take immune-suppressing drugs, you may be able to join.
SödertäljeAges 18 years+ - NCT07214571RecruitingPhase 2
Study of S-337395 for RSV in high-risk adults
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
Los Angeles, CaliforniaAges 18 years+ - NCT04099082Recruiting
Predicting lung scarring after a specific viral infection
This study looks at how your immune response to a particular virus (PIV) might predict future lung scarring called bronchiolitis obliterans. It may help doctors better identify who is at higher risk after a stem cell transplant.
Paris, Île-de-France RegionAges 18 years+
Hear when a new Respiratory Infection Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for respiratory infection virus?
- Yes. Clin2 currently lists 76 recruiting respiratory infection virus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a respiratory infection virus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a respiratory infection virus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.